论文部分内容阅读
目的探讨分析治疗植入性胎盘过程中采用米非司酮替代甲氨蝶岭的总体疗效、安全性以及可行性,为后期植入性胎盘的临床治疗工作提供科学合理的参考意见。方法回顾分析我院近年来收治治疗的56例植入性胎盘患者临床治疗的总体临床资料,按照临床治疗方式的不同分为观察组(米非司酮)和对照组(甲氨蝶岭),分析两组患者治疗后的总体疗效情况,两组植入性胎盘治疗患者的一般临床资料对比无显著差异,具有对比分析的可行性意义(P>0.05)。结果从两组植入性胎盘患者的总体治疗效果来看,其总体临床效果以及临床观察指标对比无显著性差异(P>0.05),均起到了良好的治疗效果。结论在植入性胎盘的临床治疗中采用米非司酮以及甲氨蝶岭具有安全、操作简单、止血效果明显的可行性,与甲氨蝶岭起到同样的临床治疗效果,所以可以进行替代。
Objective To explore the overall curative effect, safety and feasibility of using mifepristone instead of methotrexate in the treatment of implanted placenta, and to provide scientific and reasonable reference for the clinical treatment of implanted placenta in later period. Methods The clinical data of 56 patients with implanted placenta admitted to our hospital in recent years were retrospectively analyzed. According to the different clinical treatment methods, the patients were divided into observation group (mifepristone) and control group (methotrexate) Analysis of the two groups of patients after treatment, the overall effect of the situation, the two groups of patients with placenta accreta treatment of clinical data showed no significant difference, with the comparative analysis of the feasibility (P> 0.05). Results There was no significant difference (P> 0.05) between the two groups of implanted placenta patients in terms of the overall treatment effect, and the overall clinical effect as well as the clinical observation indicators had a good therapeutic effect. Conclusions Mifepristone and methotrexate are safe, simple and feasible to stop bleeding in the clinical treatment of implantable placenta, which has the same clinical effect as methotrexate, so it can be substituted .